Other mycobacterial diseases of other organs
ICD-10 A31.8 is a billable code used to indicate a diagnosis of other mycobacterial diseases of other organs.
A31.8 encompasses various mycobacterial infections that affect organs other than the lungs, which are primarily associated with Mycobacterium species. These infections can manifest in various forms, including cutaneous, lymphatic, and disseminated diseases. Mycobacterium avium complex (MAC) is a common cause of these infections, particularly in immunocompromised patients, such as those with HIV/AIDS. Symptoms may vary widely depending on the organ involved, ranging from localized lesions to systemic symptoms like fever and weight loss. Diagnosis typically involves culture and sensitivity testing, as well as imaging studies to assess the extent of the disease. Treatment protocols often include a combination of antibiotics, such as azithromycin and rifabutin, tailored to the specific mycobacterial species and the patient's immune status. Resistance patterns are a significant concern, particularly with MAC, where multi-drug resistance can complicate treatment regimens. Understanding the nuances of these infections is crucial for effective management and accurate coding.
Detailed clinical notes on the patient's history, symptoms, and diagnostic tests performed.
Patients presenting with fever, weight loss, and lymphadenopathy, particularly in immunocompromised individuals.
Ensure accurate documentation of the specific mycobacterial species and any resistance patterns observed.
Comprehensive pulmonary function tests and imaging studies to rule out pulmonary involvement.
Patients with respiratory symptoms who may also have extrapulmonary mycobacterial infections.
Document any respiratory symptoms thoroughly to differentiate from primary pulmonary infections.
Used when mycobacterial cultures are performed.
Document the type of culture and results.
Infectious disease specialists should ensure accurate reporting of culture results.
Symptoms can vary widely but may include fever, weight loss, localized pain, and systemic symptoms depending on the organ involved.
Diagnosis typically involves clinical evaluation, imaging studies, and microbiological confirmation through cultures or PCR testing.
Treatment often includes a combination of antibiotics tailored to the specific mycobacterial species and may require prolonged therapy, especially in immunocompromised patients.
